Actions of inhaled leukotrienes and their interactions with other allergic mediators

Barnes, Neil; Piper, Priscilla J.; Costello, J

doi:10.1016/0090-6980(84)90137-0

Cited by 45 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3). Our findings are consistent with the ob servation that LTC4 and LTD4 cause bronchoconstriction in guinea pigs through the production of TXA2 and other cy clooxygenase products [17][18][19], Since LTC4 and LTD4 have been implicated as important mediators in causing potent bronchoconstriction and in inducing airway hyperrespon siveness [28][29][30], BAY u3405 would have a therapeutic po tential for controlling asthma.…”

supporting

confidence: 78%

Effect of a Selective Thromboxane A2 Receptor Antagonist BAY u3405 on Antigen-, Leukotriene C4- and Leukotriene D4-lnduced Bronchoconstriction in Guinea Pigs

Iwamoto

Umibe²,

Nakajima³

et al. 1995

Int Arch Allergy Immunol

View full text Add to dashboard Cite

We studied the effect of a selective thromboxane (TX) A₂ receptor antagonist BAY u3405 on prostanoid-, leukotriene (LT) C₄, LTD₄- and antigen-induced bronchoconstriction in nonanesthetized guinea pigs in vivo. Oral administration of BAY u3405 inhibited bronchoconstriction induced by inhaled TXA₂ mimetic U46619, prostaglandin (PG) D₂ and PGF_2α. BAY u3405 also decreased the bronchconstriction induced by inhaled LTC₄ and LTD₄. Intraperitoneal administration of TXA₂ synthetase inhibitor OKY-046 did not affect PGD₂- and PGF_2α-induced bronchoconstriction, but attenuated LTC₄- and LTD₄-induced bronchoconstriction. BAY u3405 and OKY-046 decreased antigen-induced bronchoconstriction in actively sensitized guinea pigs. These results indicate that BAY u3405 not only inhibits TXA₂-, PGD₂- and PGF_2α-induced bronchoconstriction that is mediated through a TXA₂ receptor but also decreases LTC₄, LTD₄- and antigen-induced bronchoconstriction which is mediated in part through TXA₂ synthesis. These results suggest that BAY u3405 might be useful in controlling prostanoid-induced bronchoconstriction in asthma.

show abstract

supporting

confidence: 78%

Effect of a Selective Thromboxane A2 Receptor Antagonist BAY u3405 on Antigen-, Leukotriene C4- and Leukotriene D4-lnduced Bronchoconstriction in Guinea Pigs

Iwamoto

Umibe²,

Nakajima³

et al. 1995

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…48 More recent studies have confirmed that the airways of asthmatics are generally more responsive to CysLTs than are those of nonasthmatics, although the magnitude of the difference in responsiveness is variable. [49][50][51][52] In a study by Arm et al, 53 this difference in responsiveness between asthmatics and nonasthmatics was particularly pronounced for LTE 4 .…”

Section: Bronchoconstrictionmentioning

confidence: 99%

Role of leukotrienes in asthma pathophysiology

Bisgaard

2000

Pediatr. Pulmonol.

View full text Add to dashboard Cite

“…The time course of the enhanced airways responsiveness induced by exogenous LT aerosol was of comparable duration to that observed in the present study subsiding over a 40-60 min period. In contrast, healthy human volunteers showed unaltered airways responsiveness to histamine aerosol after inhalation of LTD, [19], but increased responsiveness to prostaglandin F2a [20] or methacholine [21]. This may suggest that species differences or the route of administration are important factors influencing these responses.…”

mentioning

confidence: 91%

Lipoxygenase metabolites mediate increased airways resonsiveness to histamine after acute platelet activating factor exposure in the guinea-pig

Anderson

Fennessy

1988

Agents and Actions

View full text Add to dashboard Cite

Platelet activating factor (Paf, 0.02 micrograms/kg, i.v. bolus) caused an acute increase in airways responsiveness to histamine in anaesthetized guinea-pigs prepared for recording airways resistance (RL) and dynamic compliance (Cdyn). Aspirin pretreatment (10 mg/kg, i.v.) attenuated the return of airways responsiveness to prechallenge levels. Pretreatment with the combined cyclooxygenase/lipoxygenase inhibitors BW 755C (20 mg/kg, i.v.) and ETYA (20 mg/kg, i.v.), or with the putative cysteinyl-containing leukotriene antagonist FPL 55712 (0.25 mg/kg/min, i.v.), or a Paf antagonist SRI 63441 (2.5 mg/kg, i.v.), prevented Paf-induced increased airways responsiveness. Inhibitors of leukotriene synthesis, BW 755C and ETYA, or action, FPL 55712, had variable effects on Paf-induced bronchoconstriction. These data suggest that lipoxygenase metabolites, possibly leukotrienes, may mediate an acute increase in airways responsiveness to histamine after Paf exposure.

show abstract

Actions of inhaled leukotrienes and their interactions with other allergic mediators

Cited by 45 publications

References 10 publications

Effect of a Selective Thromboxane A<sub>2</sub> Receptor Antagonist BAY u3405 on Antigen-, Leukotriene C<sub>4</sub>- and Leukotriene D<sub>4</sub>-lnduced Bronchoconstriction in Guinea Pigs

Effect of a Selective Thromboxane A<sub>2</sub> Receptor Antagonist BAY u3405 on Antigen-, Leukotriene C<sub>4</sub>- and Leukotriene D<sub>4</sub>-lnduced Bronchoconstriction in Guinea Pigs

Role of leukotrienes in asthma pathophysiology

Lipoxygenase metabolites mediate increased airways resonsiveness to histamine after acute platelet activating factor exposure in the guinea-pig

Contact Info

Product

Resources

About